Journal of the Canadian Association of Gastroenterology
Cure8 research brief
Why This Matters
Standardized CCPs aim to improve consistency and quality of IBD care nationwide; nationalizing 16 CCPs could help reduce regional variation and support clinicians and patients in Canada.
Who Should Pay Attention
Clinicians, health system planners, IBD patients and caregivers, organizations creating care pathways
Study Snapshot
Story typeClinical Reference
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This report summarizes a 14-month nationalization process led by a multidisciplinary team coordinated by Crohn's and Colitis Canada (PACE). The effort involved 23 health care professionals from academic and community centres and produced 16 approved CCPs covering IBD care.
Challenges included updating pathways to reflect evolving guidelines, reconciling differing clinical opinions, and scheduling constraints for contributors. The pathways were translated into French and are publicly accessible to health care providers across Canada.
The authors suggest their methods and lessons learned may help other groups creating national CCPs for chronic diseases.
Keep In Mind
Abstract-level report focused on the development and implementation process; does not present clinical outcome data or granular pathway content in the abstract.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationJournal of the Canadian Association of Gastroenterology
AuthorsChappell KD, Tausif A, Seow CH +24 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedMay 19, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
‘We need to highlight as a community that these are avoidable’: exploring clinician perspectives on healthcare access and avoidable admissions in inflammatory bowel disease
Avoidable unplanned hospital admissions are common and costly for people with IBD. This study suggests many such admissions stem from healthcare access and service delivery problems—not just disease severity—so system...
Biosimilars in inflammatory bowel disease: Beyond evidence, toward trust and implementation
Biosimilars can expand access to effective biologic treatment for people with IBD by reducing costs, but adoption barriers mean some patients may not benefit. Understanding evidence, practical concerns, and...
TIME-trend and forecasting of the economic impact of inflammatory bowel disease in Catalonia: a population-based analysis.
The study shows rapidly rising IBD healthcare costs driven mainly by growing prevalence and biologic therapy spending, which can affect access, insurance coverage, and healthcare planning for people with Crohn’s and...